Equillium, Inc.
EQ
Rank in Stocks
#19886
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on... Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
Share Price
$1.50
Last synced: 2026-11-09
Market Cap
$95.11M
Change (1 day)
-0.66%
Change (1 year)
54.48%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Equillium, Inc. (EQ)
Category
Healthcare
EPS for Equillium, Inc. (EQ)
EPS as of June 2026 TTM: $-0.26
According to Equillium, Inc.'s latest financial reports, its current EPS (TTM) is $-0.26. At the end of 2025 the company had an EPS of $-0.39, a decrease compared to its 2024 EPS of $-0.23.
EPS history for Equillium, Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.26 | -33.33% |
| 2025 | $-0.39 | 69.57% |
| 2024 | $-0.23 | -39.47% |
| 2023 | $-0.38 | -88.09% |
| 2022 | $-3.19 | 136.30% |
| 2021 | $-1.35 | -7.53% |
| 2020 | $-1.46 | -0.68% |
| 2019 | $-1.47 | 34.86% |
| 2018 | $-1.09 | 738.46% |
| 2017 | $-0.13 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -6,123.08% |
US
|
|
| $-7.07 | 2,619.23% |
US
|
|
| $-5.29 | 1,934.62% |
AU
|
|
| $12.88 | -5,053.88% |
BE
|
|
| $21.56 | -8,392.31% |
NL
|
Questions about Equillium, Inc.'s earnings per share (EPS)
What is Equillium, Inc.'s earnings per share (EPS)?
Equillium, Inc.'s earnings per share (EPS) over the last twelve months is $-0.26, as of Jun 2026.
What was Equillium, Inc.'s earnings per share (EPS) in 2025?
In 2025, Equillium, Inc.'s earnings per share (EPS) was $-0.39, compared with $-0.23 in 2024.
How has Equillium, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Equillium, Inc.'s earnings per share (EPS) was highest in 2024 ($-0.23) and lowest in 2022 ($-3.19).
How does Equillium, Inc.'s earnings per share (EPS) compare with similar companies?
Equillium, Inc.'s earnings per share (EPS) ($-0.26) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.